Posts filtered by tags: Regeneron Pharmaceuticals[x]


 

Experimental Antibody Treatment for Covid-19 Patients Wins 'Emergency Approval' in America

America's Food and Drug Administration granted emergency authorization Saturday to an experimental antibody treatment (for people already experiencing Covid-19), reports the Washington Post: The drug, made by Regeneron Pharmaceuticals, is designed to prevent infected people from developing severe illness. Instead of waiting for the body to develop its own protective immune response, the drug imitates the body's natural defenses. It is the second drug of this type — called a monoclonal antibody ...
Tags: Washington, America, Tech, Fda, New England Journal of Medicine, Lilly, Regeneron, Regeneron Pharmaceuticals, Eli Lilly Co, COVID, America s Food and Drug Administration


Regeneron halts trial of COVID-19 antibody drug in sickest hospitalized patients

Regeneron Pharmaceuticals said Friday it has paused a clinical study of its antibody drug to treat some of the sickest COVID-19 patients...
Tags: Regeneron, Regeneron Pharmaceuticals


Trial of Regeneron’s Covid-19 Antibody Drug Is Halted in Sickest Hospital Patients

Regeneron Pharmaceuticals suspended testing of its Covid-19 antibody drug in the sickest hospitalized patients because of a safety...
Tags: Regeneron, Regeneron Pharmaceuticals


12 states reported record coronavirus case counts this weekend. This could be the beginning of the second wave.

Medical technicians work at a drive-through coronavirus testing facility at the Regeneron Pharmaceuticals company's Westchester campus in Tarrytown, New York, September 17, 2020. The coronavirus outbreak appears to be getting worse across much of the US. Twelve states — Alaska, Colorado, Indiana, Kansas, Minnesota, Missouri, Montana, North Dakota, Nebraska, Oregon, South Dakota, and Utah — recorded more new infections in the last seven days than they ever have in a one-week period. T...
Tags: Fall, Utah, Science, News, Washington, Brown University, US, Trends, Cnn, Washington Dc, Deaths, Anthony Fauci, Nih, Westchester, Fauci, Tarrytown New York


More patients want to join antibody drug trials after Trump's coronavirus treatment — though we don't know yet if it actually helps COVID-19

President Donald Trump arrives at the White House on October 5, 2020, after three nights at the hospital to treat his coronavirus infection. Jabin Botsford/The Washington Post via Getty Images Coronavirus patients are asking to join clinical trials of antibody-based drugs after President Trump was given an experimental antibody therapy. Regeneron, the company that made the antibody cocktail given to Trump, told Business Insider that "generally we have seen an uptick in clinical trial inter...
Tags: Science, News, Washington Post, White House, Trends, Healthcare, News UK, Fox News, Donald Trump, Walter Reed, Trump, Reuters, University of Miami Miller School of Medicine, Brendan Mcdermid, Regeneron, Tarrytown New York


Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More

It’s October: a time of days growing shorter, leaves changing color, and phone calls in the wee hours that rouse scientists from slumber notifying them they’ve won the highest honor in their fields.This week, the 2020 Nobel Prize in physiology or medicine was awarded to Harvey Alter, Michael Alton, and Charles Rice, whose research led to the discovery of the hepatitis C virus. Their work paved the way for blood tests and new medicines that can cure the infection. In chemistry, the Nobel was awa...
Tags: Deals, Startups, Cancer, Trends, Investing, Merck, It, Software, Alzheimer's Disease, Fda, National, GlaxoSmithKline, Pfizer, Biotech, Dementia With Lewy Bodies, Cystic Fibrosis


One of Trump's COVID-19 treatments was developed using tissue that originally came from an abortion. He's tried to ban this kind of research.

President Donald Trump walks to Marine One to go to the Walter Reed medical center after he tested positive for COVID-19 on October 2, 2020. SAUL LOEB/AFP via Getty Images A treatment used on President Donald Trump after his coronavirus diagnosis was developed with testing that used cells that originally came from an abortion. The Trump administration has tried to restrict the use of such cells, though it's common practice in the development of treatments for diseases like cancer, HIV, an...
Tags: Politics, Science, White House, US, Trends, Netherlands, News UK, Abortion, National Institutes of Health, Donald Trump, Antibodies, Nih, Walter Reed, The Washington Post, Technology Review, Trump


Pelosi: Congress will discuss rules for Trump's removal under 25th amendment

Democrats plan to create commission to review president’s fitness for office as speaker warns of ‘disassociation from reality’Democrats in the US Congress have announced a plan to create a commission to review whether Donald Trump is capable of carrying out his presidential duties or should face removal from office.The office of the House speaker, Nancy Pelosi, announced a Friday press conference about the bill after she expressed concern that Trump, who is under treatment for coronavirus at the...
Tags: News, Maryland, Congress, California, Senate, White House, US, America, Joe Biden, Ukraine, Democrats, House, House Of Representatives, Nancy Pelosi, Donald Trump, Nancy


Trump calls Covid diagnosis 'blessing from God' amid false treatment claims

President returns to Oval Office despite concerns he should be self-isolating as virus spreads in White HouseDonald Trump has called his Covid-19 infection “a blessing from God” as he returned to the Oval Office on Wednesday despite concerns that he should be self-isolating, as the virus continued to spread among senior White House figures.In a video message posted to Twitter, Trump said that an experimental drug cocktail from Regeneron Pharmaceuticals was key to recovering from his infection. H...
Tags: White House, US news, US politics, US healthcare, Donald Trump, Trump, Oval Office, Twitter Trump, Regeneron Pharmaceuticals, White HouseDonald Trump, Coronavirus outbreak, COVID


Trump's experimental treatment from Regeneron puts the company in a 'very tough situation' as others request early access, CEO says

Getty President Donald Trump's use of Regeneron Pharmaceutical's experimental monoclonal antibody treatment puts the company in "a very tough situation," CEO Leonard Schleifer says. The US President was given an 8 gram injection of Regeneron's drug over the weekend under the FDA's "compassionate use" option, as Schleifer said it "just wasn't practical" to ask a government official to enter a clinical trial. But as infections in the US rise and more than 210,000 Americans have lost their l...
Tags: Health, Politics, New York, Science, White House, US, Trends, New York Times, Fda, Donald Trump, Cnbc, Trump, Melania Trump, Conley, Johns Hopkins University, Regeneron


Meet the billionaire doctors behind Regeneron, the pharmaceutical company that developed Trump's experimental COVID-19 treatment

Regeneron billionaires Leonard Schleifer and George Yancopoulos. Victor Hugo/Patrick McMullan; Victor Hugo/Patrick McMullan; Taylor Nicole Rogers/Business Insider Leonard Schleifer and George Yancopoulos, the billionaire doctors behind Regeneron Pharmaceuticals, are worth nearly $4 billion combined. President Trump took a high dose of the experimental 'antibody cocktail' that Regeneron is developing to treat his case of COVID-19. Even before he took the drug, the president was friendly wit...
Tags: New York, Life, New York City, US, Trends, Turkey, Cnn, Features, David, United States, New York Times, Billionaires, The Times, Merrill Lynch, Manhattan, Columbia University


Regeneron jumps 10% as Trump gets the drugmaker's antibody treatment while hospitalized

Cheriss May/Reuters Shares of Regeneron Pharmaceuticals leapt as high as 9.7% on Monday following news that President Trump received the drugmaker's antibody treatment while hospitalized. Regeneron's medicine is still in experimental trials, but could receive emergency use authorization for the treatment of COVID-19 by the FDA in a matter of days, according to a team of SVB Leerink analysts. Regeneron is up almost 60% year-to-date and has risen roughly 110% over the last 12 months. Watch R...
Tags: White House, Trends, Markets, Fda, Pharmaceuticals, Stock Market, Stock, Stock Price, Trump, EUA, Regeneron, Regeneron Pharmaceuticals, REGN, Experimental Medicine, Sean Conley, Biopharma


Regeneron jumps 10% as Trump gets the drugmaker's antibody treatment

Cheriss May/Reuters Shares of Regeneron Pharmaceuticals leaped as much as 9.7% on Monday following the news that President Donald Trump received the drugmaker's antibody treatment.Regeneron's medicine is still in trials but could receive emergency use authorization for treating COVID-19 from the Food and Drug Administration in days, a team of SVB Leerink analysts said.Regeneron is up almost 60% year-to-date and has risen roughly 110% over the past 12 months.Watch Regeneron trade live here....
Tags: White House, Trends, Markets, Food And Drug Administration, Pharmaceuticals, Stock Market, Donald Trump, Stock, Stock Price, Trump, Regeneron, Regeneron Pharmaceuticals, REGN, Experimental Medicine, Sean Conley, Biopharma


Hydroxychloroquine Advocate Angry Donald Trump Took 'Experimental Antibody Stupidness' (slashdot)

"A doctor notorious for claiming hydroxychloroquine is a 'cure' for COVID-19 has denounced White House doctors for not giving President Donald Trump the drug to treat his infection..." reports Newsweek. "Other unsubstantiated claims from Immanuel include declarations that fasting can cure those affected by 'witchcraft,' that having sex with demons while dreaming can cause gynecological problems and that certain medications contain the DNA of extraterrestrial aliens." Dr. Stella Immanuel, who ...
Tags: News, White House, United States, Donald Trump, Trump, Newsweek, Conley, Food and Drug Administration FDA, Immanuel, Regeneron Pharmaceuticals, EditorDavid, Leonard Schleifer, Stella Immanuel


Hydroxychloroquine Advocate Angry Donald Trump Took 'Experimental Antibody Stupidness'

"A doctor notorious for claiming hydroxychloroquine is a 'cure' for COVID-19 has denounced White House doctors for not giving President Donald Trump the drug to treat his infection..." reports Newsweek. "Other unsubstantiated claims from Immanuel include declarations that fasting can cure those affected by 'witchcraft,' that having sex with demons while dreaming can cause gynecological problems and that certain medications contain the DNA of extraterrestrial aliens." Dr. Stella Immanuel, who ...
Tags: White House, Tech, United States, Donald Trump, Trump, Newsweek, Conley, Food and Drug Administration FDA, Immanuel, Regeneron Pharmaceuticals, Leonard Schleifer, Stella Immanuel


The President’s Doctor Has Lost All Credibility

With President Trump in Walter Reed Army Hospital, the public was inevitably going to worry, wonder, and speculate about his current and longer-term health. But his doctors are making a bad situation much worse with a cascade of confusing statements, half-truths, and rosy assessments at a time when transparency is vital.At best, his team is inviting confusion and fear after getting caught up in a White House trying to reassure the public but doing the opposite. At worst, they are misleading the ...
Tags: News, Supreme Court, Congress, Cdc, White House, Gop, United States, New York Times, Fox News, Associated Press, Cleveland, Walter Reed, Ron Johnson, Trump, Conley, Rose Garden


Trump COVID-19 treatment: President had stakes in Regeneron and Gilead, makers of antibody cocktail, Remdesivir

President Trump previously reported he earned capital gains from Regeneron Pharmaceuticals and Gilead Sciences Inc., makers of COVID-19 treatments.         [Author: USA TODAY]
Tags: Usa, News, Usa Today, Trump, Gilead Sciences Inc, Gilead, Regeneron, Regeneron Pharmaceuticals


Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More

Amid the bombast of Tuesday’s presidential debate, viewers caught some discussion about the response to the coronavirus pandemic and efforts to develop a COVID-19 vaccine. In the crosstalk, the president made an unsupported claim that we are weeks away from having vaccines.It’s true that some pharmaceutical companies are already manufacturing their COVID-19 vaccine candidates for broader use. This production ensures that vaccine product is ready for distribution upon receiving a regulatory deci...
Tags: Deals, Startups, Trends, Investing, Merck, Alzheimer's Disease, Astrazeneca, Fda, National, Type 2 Diabetes, Pfizer, Parkinson's Disease, Biotech, Galapagos, Life Sciences, Bayer


A spate of advancements suggest new coronavirus treatments could be on the horizon — here's the latest

Investigational remdesivir vials at a Gilead Sciences facility in La Verne, California. Reuters The landscape of potential COVID-19 treatments is changing quickly.  Two potential therapies from pharma giant Eli Lilly — an antibody drug and an arthritis pill — saw promising results in recent weeks.  An antibody drug from biotech company Regeneron was also found to lowered the amount of virus detected in patients' samples. Growing evidence also shows that steroids improve outcomes in severe ...
Tags: UK, Science, News, China, Trends, Who, World Health Organization, Fda, University of Oxford, Anthony Fauci, Baltimore, Business Insider, Steroids, Roche, Gilead Sciences, Provo Utah


5 potential coronavirus treatments have seen major advancements this month — here's what the new research shows

Investigational remdesivir vials at a Gilead Sciences facility in La Verne, California. Reuters The landscape of potential COVID-19 treatments is changing quickly.  Two potential therapies from pharma giant Eli Lilly — an antibody drug and an arthritis pill — saw promising results this month.  An antibody drug from biotech company Regeneron also entered a major clinical trial last week. Meanwhile, new data suggests that the rheumatoid arthritis drug Actemra and steroids like hydrocortisone...
Tags: UK, Science, News, China, Trends, Who, World Health Organization, Fda, Anthony Fauci, Baltimore, Steroids, Roche, Gilead Sciences, Provo Utah, Port au Prince Haiti, Heilongjiang province


Regeneron's COVID-19 antibody-drug cocktail treats SARS-CoV-2 virus in animals

Now, Regeneron Pharmaceuticals says its COVID-19 antibody-drug cocktail under development prevented and treated the disease in monkeys and hamsters, showing promise that it may work in humans.
Tags: Health, Regeneron, Regeneron Pharmaceuticals


AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis

The body’s natural process for healing wounds has led AsclepiX Therapeutics to a novel approach to treating diseases of the eye. The startup is now gearing up to test its technology in humans, and it has raised $35 million in Series A financing to support its research.Cuts and scrapes in the skin spark the formation of new blood vessels and connective tissue that fills the wound. But this process, called angiogenesis, does not continue indefinitely. Within days the body returns to a state of eq...
Tags: Deals, Startups, Trends, Investing, It, Software, National, Biotech, Life Sciences, Bayer, Clinical Trials, Roche, Johns Hopkins University, Ranibizumab, Regeneron Pharmaceuticals, Diabetic Macular Edema


Researchers identify potent antibody cocktail to treat COVID-19

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail and used as a promising anti-viral therapy against the virus that causes COVID-19. Their research, conducted in collaboration with scientists at Regeneron Pharmaceuticals, was published yesterday in the journal Science.
Tags: Science, Regeneron Pharmaceuticals, University of Maryland School of Medicine UMSOM


Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More

At the start of 2020 thousands of biotechies anticipated spending the second week of June in San Diego, hobnobbing at the annual conference hosted by the Biotechnology Innovation Organization.Instead, attendees from 64 countries spanning 28 times zones convened online this week for the first-ever virtual BIO International Convention. There, topics once as unanticipated as the remote nature of the meeting shared top billing: COVID-19 and racism. Infectious disease experts opined on the industry’...
Tags: Deals, Startups, Trends, Diversity, Merck, Racism, Incubator, Venture Capital, San Diego, M&a, Astrazeneca, National, Pfizer, Vaccine, Abbvie, Biotech


DNAnexus raises $100M for a cloud-based analytics platform aimed at genomics and other clinical big data

DNAnexus, which provides a cloud platform for governments, universities, doctors, and pharmaceutical companies to tap into DNA and other clinical datasets and collaborate on scientific research projects, is today announcing a big step ahead in its efforts to grow its reach and purpose. The 10 year-old startup, originally spun out of Stanford’s school of medicine, has raised $100 million in funding. The round, technically a Series G, is being co-led by Perceptive Advisors and Northpond Ventures (...
Tags: Startups, UK, Science, Microsoft, Stanford, Funding, Tech, Food And Drug Administration, Biotech, Rosetta Stone, Michael Rubin, Regeneron Pharmaceuticals, Perceptive Advisors, Recent Funding, Northpond Ventures, Richard Daly


Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact

Four years after Regeneron Pharmaceuticals and Intellia Therapeutics began working together to research the use of CRISPR/Cas9 to treat liver diseases, the partners are expanding their pact to bleeding disorders.The deal announced Monday covers the development of potential treatments for hemophilia, which stems from genetic mutations that lead to insufficient levels of blood clotting proteins. The revised alliance covers the joint development of potential treatments for both hemophilia A and B....
Tags: Deals, New York, Trends, Pfizer, Biotech, Crispr, Life Sciences, Clinical Trials, Gene Editing, John Leonard, Regeneron, Regeneron Pharmaceuticals, Gene Therapy, CRISPR/Cas9, BioMarin Pharmaceutical, Intellia Therapeutics


Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More

A year ago about 40,000 people gathered in Chicago for the annual meeting of the American Society of Clinical Oncology. Today a virtual version of the ASCO conference, the cancer field’s largest, kicks off, with oncologists and others tuning in from throughout the country and around the world to check out the latest in cancer research.ASCO 2020 won’t be the Windy City gathering it usually is, but drug and diagnostics developers are still raring to share fresh data from their efforts in cancer i...
Tags: Startups, Ipo, Funding, Trends, Merck, Chicago, Alzheimer's Disease, Incubator, Stem Cells, Venture Capital, Machine Learning, Fda, National, Contraception, GlaxoSmithKline, Ai


US coronavirus drugmaker Regeneron to buy back $5B stake held by Sanofi

Regeneron Pharmaceuticals said it had agreed to repurchase approximately $5 billion of its shares directly from French drugmaker Sanofi.
Tags: Finance, US, Article, Reuters, Sanofi, FBN, Regeneron, Regeneron Pharmaceuticals, Fbn/markets, Fox-business/markets/stocks, Fox-business/health-care, 0688232e-6d47-50f4-adf1-a418393374e9


U.S.' Regeneron to buy back $5 billion stake held by Sanofi

U.S. company Regeneron Pharmaceuticals said it had agreed to repurchase approximately $5 billion of its shares directly from French drugmaker Sanofi.
Tags: Money, businessNews, Sanofi, Regeneron, Regeneron Pharmaceuticals


Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More

Alexion Pharmaceuticals CEO Ludwig Hantson has made no secret that he wants to diversify his company’s drug portfolio and he has shown willingness to open the corporate checkbook to accomplish that goal.Last October, Alexion (NASDAQ: ALXN) struck a $930 million deal to acquire Achillion Pharmaceuticals, a biotech whose lead drug complements the Boston company’s own therapies for rare blood diseases. This week, Alexion agreed to pay $1.4 billion for Portola Pharmaceuticals, whose main product tr...
Tags: Startups, Boston, Cancer, Trends, Investing, Astrazeneca, National, Epilepsy, Novartis, Pfizer, Abbvie, Biotech, Microbiome, Crispr, Chemotherapy, Federal Trade Commission